Anthropicの「AI for Science」희귀疾患研究グラント募集開始Apply for Anthropic’s AI for Science rare disease research grants

Anthropic has opened applications for a new round of grants under its AI for Science program, this time focused specifically on researchers working on rare diseases. The initiative offers selected scientists access to Claude, the company's family of large language models, with the stated aim of accelerating progress on conditions that currently lack adequate treatments. The move matters because rare diseases collectively affect a large population yet attract comparatively little commercial research investment, leaving many patients without approved therapies.

Rare diseases are typically defined as conditions affecting a small number of people relative to the general population, though the precise threshold varies by jurisdiction. Estimates commonly cited by patient organizations suggest there are more than 7,000 distinct rare diseases and that hundreds of millions of people worldwide live with one. A significant majority are believed to have a genetic origin, and the overwhelming share have no approved treatment. Because each condition affects relatively few individuals, the economic incentives for traditional drug development are often weak, and researchers frequently work with limited funding, small patient cohorts, and fragmented data.

According to Anthropic, the grants are intended to help address some of these gaps by giving researchers computational tools that can assist with tasks such as literature synthesis, hypothesis generation, data analysis, and the interpretation of complex biological information. Large language models like Claude are positioned as general-purpose assistants that can help scientists parse dense scientific literature, draft and refine research plans, and reason through experimental design. The company frames this as complementary to, rather than a replacement for, domain expertise and laboratory work.

The rare disease grants sit within Anthropic's broader AI for Science effort, which the company has described as an attempt to support researchers using its models for scientific discovery, particularly in biology and the life sciences. That program has previously offered credits and access to Claude for academic and nonprofit researchers. By narrowing the focus to rare diseases in this cycle, Anthropic appears to be targeting an area where AI assistance could have outsized value given the scarcity of both funding and specialized human expertise, though the real-world impact of such tools on clinical outcomes remains to be demonstrated.

It is worth situating this announcement within a wider industry trend of applying artificial intelligence to biomedical research. Google DeepMind's AlphaFold, which predicts protein structures, is perhaps the most prominent example and has been widely adopted across the life sciences; its creators were recognized with a share of the 2024 Nobel Prize in Chemistry. Isomorphic Labs, a DeepMind spinout, is pursuing AI-driven drug discovery, and numerous startups and pharmaceutical companies have invested in machine learning for target identification and molecule design. Language models specifically have been explored for tasks including summarizing biomedical literature, extracting structured data from clinical text, and supporting diagnostic reasoning, although concerns about accuracy, hallucination, and the need for expert verification persist.

For prospective applicants, the practical value of the grants is likely to depend on how well general-purpose language models integrate with the specialized workflows of rare disease research, which often involve genomic data, patient registries, and highly technical clinical knowledge. Claude and comparable systems can process and summarize large volumes of text and reason over provided information, but they can also produce plausible-sounding errors, which makes human oversight essential in a medical context. Anthropic has generally emphasized safety and reliability as part of its positioning, and researchers using these tools would still be responsible for validating any outputs before they inform experiments or clinical decisions.

The company has not, in this summary, detailed the size of individual awards, the number of recipients, or the specific eligibility and selection criteria, and interested researchers would need to consult the official application materials for those particulars. As with many AI-for-science initiatives, the announcement also serves a strategic purpose for the provider, helping to build relationships with the research community, gather feedback on how its models perform on demanding technical tasks, and demonstrate socially beneficial applications of its technology. Whether the grants translate into meaningful acceleration of rare disease research will become clearer as funded projects progress and publish their results.